Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 2Phase NA 1

Status

Unknown 2

Sponsor Class

INDUSTRY 237OTHER 166NETWORK 34NIH 30OTHER_GOV 5UNKNOWN 2FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Neoplasm Metastasis 2Breast Neoplasms 2Skin Diseases 1Neoplasms by Site 1Carcinoma, Ductal, Breast 1Breast Diseases 1

Interventions

Paclitaxel 6Radiotherapy 3Epirubicin 3Radiotherapy, Intensity-Modulated 2Radiation Dose Hypofractionation 2Radiation 2Docetaxel 2Cyclophosphamide 2Cisplatin 2Carboplatin 2Capecitabine 2pegylated granulocyte colony-stimulating factor 1nabiximols 1aumolertinib 1Zoledronic Acid 1Vinorelbine 1Temozolomide 1TP protocol 1Standard of Care 1S 1 (combination) 1Platinum 1Pemetrexed 1Neoadjuvant Therapy 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Drug Therapy 1Decitabine 1Chemotherapy, Adjuvant 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × UNKNOWN × Docetaxel × Clear all
NCT01917279 2020-07-23

CAMELLIA

ChineseAMS

Phase 3 Unknown
280 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Skin Diseases

NCT01126138 2011-05-04

Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)

ChineseAMS

Phase 3 Unknown
200 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Carcinoma, Ductal, Breast

Data powered by HemOnc (CC BY 4.0) Colophon âš¡